1. Market Research
  2. > Biotechnology
  3. > Medical Biotechnology Market Trends
Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

  • August 2016
  • ID: 4100752
  • Format: PDF
  • By GlobalData

Summary

Table of Contents

Search Inside

Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation

Summary

Rheumatoid Arthritis (RA) is a chronic, progressive and currently incurable auto-immune disease that affects the joints, and is characterized by synovial inflammation and hyperplasia. It occurs when a number of aberrant cell signaling events trigger chronic inflammation of the synovium – the soft tissue of the joint – leading to pain, joint stiffness, and eventually deformity and disability.

In particular, the diversification in pharmaceutical therapeutics has led to a transformation in both the clinical and commercial landscape, with the advent of biologic agents. These therapies have greatly improved treatment options for a large proportion of patients who respond inadequately, are intolerant or have contraindications to first-line treatments such as methotrexate (MTX). Tumor necrosis factor (TNF)-? targeting biologics have proved to be particularly lucrative. Humira (adalimumab), Enbrel and Remicade (infliximab) are all well-established mega-blockbusters, and in 2015 generated global revenue of $14.4 Billion, $9.3 Billion and $9.2 Billion, respectively.

The RA pipeline is relatively large, containing 454 products. The proportion of first-in-class products in the pipeline is marginally lower than the industry average, but despite this it contains many promising first-in-class targets that have the potential to lead to therapeutic advances. In particular, there is a higher proportion and diversity of first-in-class molecular targets in the early development stages than in the clinical trial development stages.

While the RA pipeline largely constitutes developmental therapeutics with established molecular targets, a range of highly innovative developments have also emerged, with molecular targets that have not been reported for any marketed product across any indication in the industry. This reflects a growing understanding of the signaling pathways underlying RA pathophysiology.

The report “Frontier Pharma: Rheumatoid Arthritis - Cytokine Mediators and Kinase Inhibitors Dominate First-in-Class Product Innovation” provides you to identify the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options. Additionally, this report Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market and helps you to recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.

Companies mentioned in this report: Boehringer Ingelheim, Novartis, Sareum, Portola Pharmaceuticals, AB2 Bio, Pfizer, Xalud Therapeutics, Weizmann Institute of Science, Medestea Research & Production, Astellas, Radikal Therapeutics, Metabolab, Jyant Technologies, Vaccinex.

Scope

Treatment options for RA have advanced over the past two decades, resulting in a crowded, competitive market landscape.
- What is the pathophysiology of RA?
- Which products and therapeutic strategies dominate the clinical and commercial landscapes?
- What are the most significant unmet needs within the RA market?
Considerable diversification from current market trends is evident within the RA pipeline.
- Which molecular targets are most prominent within the pipeline?
- What proportion of pipeline products are first in class?
- Which first-in-class targets are most promising?
Deal values for licensing and co-development deals vary considerably.
- How many strategic consolidations have been completed in the past decade?
- Which types of assets attract the largest deal values?
- Which first-in-class pipeline products have no prior involvement in licensing or co-development deals?

Reasons to buy

This report will allow you to -
- Appreciate the current clinical and commercial landscapes by considering disease pathogenesis, etiology, epidemiology, symptoms, co-morbidities and complications, diagnosis, and treatment options.
- Visualize the composition of the RA landscape, including key unmet needs, in order to gain a competitive understanding of gaps in the current market.
- Recognize innovative pipeline trends by analyzing therapies by stage of development, molecule type and molecular target.
- Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, all first-in-class targets in the RA pipeline have been assessed and ranked according to clinical potential. Promising early-stage targets have been further reviewed in greater detail.
- Identify first-in-class pipeline products with no prior involvement in licensing and co-development deals that may represent potential investment opportunities.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
25% Off

($6995)

  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019

Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, H2 2019SummaryAccording to the recently published report ’Tumor Necrosis Factor Receptor Superfamily Member 1A - Pipeline Review, ...

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019SummaryThis latest Pharmaceutical and Healthcare disease pipeline guide Chemotherapy Induced Neutropenia - Pipeline Review, H2 2019, provides ...

Nasal Polyps - Pipeline Review, H2 2019

Nasal Polyps - Pipeline Review, H2 2019

  • $ 2000
  • November 2019

Nasal Polyps - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps - Pipeline Review, H2 2019, provides an overview of the Nasal Polyps (Ear Nose ...

Uveitis - Pipeline Review, H2 2019 $ 2000 November 2019


ref:plp2016

Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on